Live Breaking News & Updates on L Harbert Institute For Innovation

Stay updated with breaking news from L harbert institute for innovation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Encouraging Phase 1 data for glioblastoma treatment

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma. ....

United States , Trishna Goswami , Larry Lamb , Burt Nabors , Mina Lobbous , American Society Of Clinical Oncology , Oneal Comprehensive Cancer Center , L Harbert Institute For Innovation , O Neal Comprehensive Cancer Center , Medicine Department , Clinical Oncology , Annual Meeting , Cleveland Clinic ,